Allotment of New Equity

12830687_1


NZX Release 31 March 2021
Allotment of New Equity
Promisia Healthcare Limited (NZX: PHL) (PHL) is pleased to announce the final uptake on its share
purchase plan (SPP) and allotment of shares under the SPP.

PHL received 304 applications in the SPP raising approximately $1.7 million. The Board is very pleased
with the level of uptake as it will provide valuable working capital and allow PHL to pursue further
development and acquisitions in order to increase shareholder value.

PHL is also pleased to advise that approximately $450,000 of new shares are also being issued today
at an issue price of $0.001 per share to several wholesale investors. This takes the total cash raised by
PHL to approximately $10 million since October last year.

The Board has also resolved to issue the remaining Capitalisation Shares to Thomas David Brankin and
Michael John Kirwin Lay as trustees of the Brankin Family Interest Trust (Brankin Family Interest
Trust), which was approved by shareholders at the special meeting of shareholders held 24 March
2021.

A capital change notice detailing the share issues accompanies this announcement.

PHL wishes to thank shareholders that participated in the SPP for their ongoing support.

ENDS

For further information please contact Mr Stephen Underwood, Chairman on 027 499 3387.

---

Capital Change Notice


12821817_1


Section 1: Issuer information
Name of issuer Promisia Healthcare Limited (PHL)
NZX ticker code PHL
Class of financial product Ordinary shares
ISIN NZPRPE0001S5
Currency New Zealand Dollars
Section 2: Capital change details
Number issued/acquired/redeemed 3,035,228,100 shares being:
• 862,683,100 fully paid ordinary
shares (Remaining
Capitalisation Shares);
• 1,674,145,000 fully paid
ordinary shares (SPP Shares);
and
• 468,400,000 fully paid ordinary
shares (Placement Shares).
Nominal value (if any) Not applicable
Issue/acquisition/redemption price per security $0.001
Nature of the payment (for example, cash or other
consideration)
Consideration for the Remaining
Capitalisation Shares being the
capitalisation of amounts owing by PHL
to the Brankin Family Trust.

Consideration for the SPP Shares and
Placement Shares being cash.
Amount paid up (if not in full) Not applicable
Percentage of total class of Financial Products
issued/acquired/redeemed/ (calculated on the number of
Financial Products of the Class, excluding any Treasury Stock,
in existence)
14.44%
For an issue of Convertible Financial Products or Options, the
principal terms of Conversion (for example the Conversion
price and Conversion date and the ranking of the Financial
Product in relation to other Classes of Financial Product) or the
Option (for example, the exercise price and exercise date)
Not applicable
Reason for issue/acquisition/redemption and specific authority
for issue/acquisition/redemption/ (the reason for change must
be identified here)
For the Remaining Capitalisation
Shares, reducing liabilities.
For the SPP Shares and Placement
Shares, increasing working capital.
Authorised by board resolutions and
shareholder approval.
Total number of Financial Products of the Class after the
issue/acquisition/redemption/Conversion (excluding Treasury
Stock) and the total number of Financial Products of the Class
held as Treasury Stock after the issue/acquisition/redemption.
21,024,708,884
In the case of an acquisition of shares, whether those shares
are to be held as treasury stock
Not applicable

Specific authority for the issue, acquisition, or redemption,
including a reference to the rule pursuant to which the issue,
acquisition, or redemption is made
Shareholders approved the issue of up
to 1,557,681,100 on 24 March 2021
under listing rule 4.2.1(a) under which
the Remaining Capitalisation Shares
have been authorised.

Shareholders approved the issue of up
to 5 billion shares on 11 June 2020
under listing rule 4.2.1(a) under which
the SPP Shares have been authorised.

The Board has approved the issue of
the Placement Shares under PHL’s 15%
Placement capacity under listing rule
4.5.
Terms or details of the issue, acquisition, or redemption (for
example: restrictions, escrow arrangements)
New ordinary shares that rank equally
with existing ordinary shares.
Date of issue/acquisition/redemption 31 March 2021
Section 3: Authority for this announcement and contact person
Name of person

authorised to make this announcement Stephen Underwood
Contact person for this announcement Stephen Underwood
Contact phone number +64 27 499 3387
Contact email address stephen@renouf.co.nz
Date of release through MAP

31 March 2021